SCHEMBL2947194

SCHEMBL2947194

O=C(O)Cn1c(=O)oc2ccccc21

nearest known ligand 0.74

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.73
MAPK1 P28482 3/20 0.66
TSHR P16473 2/20 0.66
USP2 O75604 1/20 0.66
MIF P14174 1/20 0.63
IDO1 P14902 2/20 0.62
ALDH1A1 P00352 3/20 0.61
LMNA P02545 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
HTT P42858 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6204691 0.85 IDO1 (0.79) HPGDMAPK1TSHRUSP2MIF
SCHEMBL13995838 0.85 HPGD (0.71) HPGDMAPK1TSHRUSP2IDO1
SCHEMBL4414345 0.85 HPGD (1.00) HPGDMAPK1TSHRUSP2MIF
Benzene SCHEMBL7861838 0.83 MAPK1 (0.75) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL2008321 0.83 MAPK1 (0.75) HPGDMAPK1TSHRUSP2ALDH1A1
SCHEMBL5418750 0.82 TSPO (0.58)
SCHEMBL11192533 0.81 MAPT (0.53) HPGDMAPK1ALDH1A1LMNASMN1; SMN2
SCHEMBL6717405 0.81 HPGD (0.66) HPGDMAPK1TSHRUSP2IDO1
SCHEMBL4427310 0.81 LMNA (0.71) HPGDLMNA
SCHEMBL29004242 0.81 LMNA (0.71) HPGDMAPK1TSHRUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240408107-A1 LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2024-12-12 US disclosed
US-20240158386-A1 BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-05-16 US disclosed
WO-2023060134-A1 LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-04-13 WO disclosed
WO-2022187804-A1 BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-09-09 WO disclosed
EP-2768822-B1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARM SPA (IT) 2017-12-06 EP disclosed
EP-2809668-B1 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2017-04-12 EP disclosed
US-9266876-B2 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2016-02-23 US disclosed
US-9024027-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-05-05 US disclosed
US-9024027-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-05-05 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
WO-2004091604-A1 COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION WARNER-LAMBERT COMPANY LLC (US) 2004-10-28 WO disclosed
WO-2004089302-A2 POSH POLYPEPTIDES, COMPLEXES AND RELATED METHODS PROTEOLOGICS, INC. (US) 2004-10-21 WO disclosed
US-20040209936-A1 Compounds that modulate PPAR activity and methods of preparation BRATTON LARRY D (US) 2004-10-21 US disclosed
WO-2004078130-A2 POSH INTERACTING PROTEINS AND RELATED METHODS PROTEOLOGICS, INC. (US) 2004-09-16 WO disclosed
WO-2004073609-A2 POSH ASSOCIATED KINASES AND RELATED METHODS PROTEOLOGICS, INC. (US) 2004-09-02 WO disclosed
CN-1492874-A Macrolide antibiotics 2004-04-28 CN disclosed
EP-0509769-B1 Heterocyclic amides having HLE inhibiting activity ZENECA LTD (GB) 1996-09-11 EP disclosed
US-5521179-A Heterocyclic amides ZENECA LIMITED (GB) 1996-05-28 US disclosed
EP-0509769-A2 Heterocyclic amides having HLE inhibiting activity ZENECA LIMITED (GB) 1992-10-21 EP disclosed
EP-0350163-A2 Renin inhibitory peptides BEECHAM GROUP PLC (GB) 1990-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158386-A1 BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES NLRP3, NLRP1, PYCARD HPGD 3270/4885MAPK1 1857/4885TSHR 4431/4885
US-20040209936-A1 Compounds that modulate PPAR activity and methods of preparation PPARA, PPARG, PPARD HPGD 691/4885MAPK1 1366/4885TSHR 613/4885
US-20240408107-A1 LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS PDK1, PKM, PDK3 HPGD 914/4885MAPK1 706/4885TSHR 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.